Korro Bio narrows second quarter 2026 net loss to $18.9M and extends cash runway into the second half of 2028.

Korro Bio reported a net loss of $18.9 million, or ($1.07) per share, for the second quarter of 2026, with no collaboration revenue recognized. The company highlighted progress in its pipeline, including the nomination of a new development candidate and plans to initiate a clinical trial for its lead program in the second half of the year.

Key Highlights

• Ended the second quarter with $137.9 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into the second half of 2028.
• Research and development expenses decreased to $13.6 million from $20.1 million in the prior-year period, primarily due to lower external expenses for the KRRO-110 program.
• Nominated KRRO-111 as a development candidate for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
• The lead program, KRRO-121, for hyperammonemia remains on track to begin its first-in-human clinical trial in the second half of 2026.